Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790101 · ClinicalTrials.gov registry record · Phase 4
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
A Phase 4 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00790101 is a Phase 4 study that was terminated before completion, run by Sanofi. The registered enrollment target is 6 participants.
The verdict
NCT00790101, a Phase 4 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
Interventions
- OTHER Placebo
- DRUG Risedronate
- DRUG Raloxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-06 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790101
The ClinicalTrials.gov registry entry for NCT00790101 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00790101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790101 about?
NCT00790101 is a clinical study titled "Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation". This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
What is the current status of trial NCT00790101?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2004-06. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00790101?
The interventions under investigation include: Placebo (OTHER), Risedronate (DRUG), Raloxifene (DRUG).
Who is sponsoring clinical trial NCT00790101?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.